## Francesco Vizzutti

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3839317/francesco-vizzutti-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48 3,591 23 49 h-index g-index citations papers 6.1 4,042 49 4.45 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
48	Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study <i>Annals of Hepatology</i> , <b>2022</b> , 27, 100683	3.1	O
47	Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 339-347	3.7	2
46	Characterization of lymphocyte subsets in ascitic fluid and peripheral blood of decompensated cirrhotic patients with chronic hepatitis C and alcoholic liver disease: A pivotal study. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2020</b> , 34, 2058738420929587	3	O
45	Alcohol use disorder and liver transplant: new perspectives and critical issues. <i>Korean Journal of Internal Medicine</i> , <b>2020</b> , 35, 797-810	2.5	1
44	Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 37-48	3.7	15
43	Super-Resolution Microscopy Reveals an Altered Fibrin Network in Cirrhosis: The Key Role of Oxidative Stress in Fibrinogen Structural Modifications. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	2
42	Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 870-874	3.3	1
41	Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients. <i>Liver International</i> , <b>2018</b> , 38, 1253-1262	7.9	24
40	Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1153-1162.e7	6.9	53
39	Consensus conference on TIPS management: Techniques, indications, contraindications. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 121-137	3.3	60
38	Paradoxical embolization in TIPS: take a closer look to the heart. <i>Annals of Hepatology</i> , <b>2015</b> , 14, 127-31	3.1	2
37	The metabolic syndrome and chronic liver disease. Current Pharmaceutical Design, 2014, 20, 5010-24	3.3	27
36	n-3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis. <i>Liver International</i> , <b>2014</b> , 34, 918-30	7.9	15
35	Acute on chronic liver failure: From pathophysiology to clinical management. <i>Trends in Anaesthesia and Critical Care</i> , <b>2013</b> , 3, 122-129	0.4	6
34	Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. <i>Gastroenterology</i> , <b>2013</b> , 144, 102-111.e1	13.3	336
33	Hepato-systemic gradient of carbon monoxide in cirrhosis. <i>European Journal of Internal Medicine</i> , <b>2012</b> , 23, e14-8	3.9	2
32	Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. <i>Clinical Science</i> , <b>2012</b> , 123, 459-71	6.5	48

## (2008-2011)

31	Elevated plasma levels of urotensin II do not correlate with systemic haemodynamics in patients with cirrhosis. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 314-8	3.3	4
30	Curcumin limits the fibrogenic evolution of experimental steatohepatitis. <i>Laboratory Investigation</i> , <b>2010</b> , 90, 104-15	5.9	72
29	Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. <i>Blood</i> , <b>2010</b> , 116, 335-42	2.2	97
28	Cellular and molecular basis of fibrogenesis in NASH. <i>Arab Journal of Gastroenterology</i> , <b>2010</b> , 10, S35-S	537 <sub>1.7</sub>	
27	Increased plasma carbon monoxide in patients with viral cirrhosis and hyperdynamic circulation. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 891-7	0.7	18
26	Elastography for the non-invasive assessment of liver disease: limitations and future developments. <i>Gut</i> , <b>2009</b> , 58, 157-60	19.2	33
25	Reply:. <i>Hepatology</i> , <b>2009</b> , 49, 1054-1055	11.2	
24	Ascites due to pericardial cyst. <i>Internal and Emergency Medicine</i> , <b>2009</b> , 4, 449-50	3.7	1
23	Expanding the severity range of polytetrafluoroethylene-related hepatic outflow occlusion. <i>Liver International</i> , <b>2009</b> , 29, 1288-9	7.9	1
22	Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 1102-11	13.4	150
21	Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. <i>Gastroenterology</i> , <b>2009</b> , 136, 160-7	13.3	195
20	Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2009</b> , 8, 89-94	3.1	17
19	Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , <b>2008</b> , 5, 95-106		133
18	Fibrosis and cirrhosis reversibility: clinical features and implications. <i>Clinics in Liver Disease</i> , <b>2008</b> , 12, 901-13, x	4.6	55
17	Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. <i>Hepatology</i> , <b>2008</b> , 47, 668-76	11.2	97
16	Acute viral hepatitis increases liver stiffness values measured by transient elastography. <i>Hepatology</i> , <b>2008</b> , 47, 380-4	11.2	556
15	Reply:. <i>Hepatology</i> , <b>2008</b> , 47, 2140-2141	11.2	2
14	Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. <i>Hepatology</i> , <b>2008</b> , 48, 442-8	11.2	292

13	Reply:. <i>Hepatology</i> , <b>2008</b> , 48, 350-350	11.2	9
12	Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. <i>Hepatology</i> , <b>2007</b> , 45, 1290-7	11.2	512
11	Performance of Doppler ultrasound in the prediction of severe portal hypertension in hepatitis C virus-related chronic liver disease. <i>Liver International</i> , <b>2007</b> , 27, 1379-88	7.9	27
10	Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. <i>Journal of Hepatology</i> , <b>2007</b> , 46, 230-8	13.4	86
9	Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. <i>American Journal of Physiology - Renal Physiology</i> , <b>2006</b> , 290, G120-8	5.1	18
8	Portal hypertension secondary to myelofibrosis: a study of three cases. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 2355-8	0.7	26
7	Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. <i>Hepatology</i> , <b>2005</b> , 42, 1339-48	11.2	276
6	Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 4266-74	12.9	19
5	Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. <i>Gastroenterology</i> , <b>2004</b> , 126, 886-94	13.3	198
4	Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis. <i>Clinical Science</i> , <b>2004</b> , 106, 27-34	6.5	19
3	Cardiovascular effects of canrenone in patients with preascitic cirrhosis. <i>Hepatology</i> , <b>2002</b> , 35, 1441-8	11.2	13
2	Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. <i>Hepatology</i> , <b>2001</b> , 34, 19-27	11.2	66
1	Ascites and hepatorenal syndrome. European Journal of Gastroenterology and Hepatology, <b>2001</b> , 13, 313	3 <b>-6</b> .2	5